A summarized information of patents on sofosbuvir, ledipasvir and daclatasvir in parts of South and south-east Asia. The documents also covers situation of registration of these medications in the countries as on August 2015..read full document
Bangkok 11 August 2015 TREAT Asia just published an overview documentation on Sofosbuvir, the snapshot provides a brief summary of the medication, its regulatory approvals, treatment response data from early clinical trials and pricing information. Click here to see the full document
Hepatitis C Treatment Without Borders is a social media page dedicated to spread hepatitis C information and mobilize social action. Bounded together in solidarity to help access equitable access to life-saving drugs and to provide hope and optimism to a world where human suffering takes second place to corporate greed ...
Under GILEAD licenses generic Sofosbuvir is available in India since March 2015, this is the latest information regarding availability and price of generic Sofosbuvir drugs in India as on 15 June 2015..see the full list
26 May 2015 Indonesia AIDS Coalition (IAC) wrote a letter to BPOM (Indonesian Food and Drugs Authority) to expedite the registration process of DAA medicines in Indonesian market. Click to see the full letter in Bahasa Indonesia or English
Source: http://www.msfaccess.org MSF is in the process of starting to treat people who are living with hepatitis C virus (HCV) in at least nine countries, and therefore is in need of affordable access to direct acting antiviral (DAA) treatments, including those marketed by Gilead Sciences (Gilead) and Bristol-Myers Squibb (BMS). There are legal ...
Under GILEAD licenses generic Sofosbuvir is available in India since March 2015, this is the latest information regarding availability and price of generic Sofosbuvir drugs in India as on 18 May 2015..read full document
2nd May 2015 - Stepping up efforts to counter patents on life-saving medicines, three civil society groups working to increase access to affordable, life-saving Hepatitis C (HCV) medicines, have challenged Bristol-Myers Squibb (BMS’) pending patent application on Daclatasvir before the Delhi Patent Office. The pre-grant opposition filed by Hepatitis Coalition, ...
March 25, 2015 - A letter from Civil Society Organizations in Asia and Eastern Europe to the Global Fund Board in advance of its Thirty-Third Meeting regarding the role of the Global Fund in providing and scaling up access to hepatitis C treatment…read full letter
March 2015 – WHO published the updated working paper on Sofosbuvir as key medicine for Hep C treatment and describes the relevant patents for Sofosbuvir and providing data where these patents have been filed or granted…read more